系统性疫苗接种诱导CD8+T细胞并重塑瘤微环境
Faezzah Baharom1, Ramiro A Ramirez-Valdez2, Ahad Khalilnezhad3
1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; Genentech, South San Francisco, CA 94080, USA.
Cell
|October 27, 2022
概括
通过使用纳米粒子疫苗进行静脉注射,通过减少抑制性骨髓细胞,有效地回归瘤. 这种方法增强了抗瘤T细胞免疫力,并重塑瘤微环境 (TME) 以改善癌症免疫治疗.
科学领域:
- 免疫学
- 癌症学
- 纳米技术
背景情况:
- 治疗癌症的疫苗旨在增强瘤特异性T细胞免疫力.
- 瘤微环境 (TME) 通常包含抑制机制, 阻碍T细胞功能.
- 了解疫苗接种途径如何影响TME内的髓状细胞对于有效的免疫治疗至关重要.
研究的目的:
- 研究疫苗接种方式对内髓细胞群的影响.
- 通过不同的途径进行纳米粒子疫苗 (SNP-7/8a) 的疗效评估.
- 通过疫苗接种改变TME并影响瘤回归的机制.
主要方法:
- 使用自组装纳米粒子疫苗 (SNP-7/8a),将瘤抗原与Toll-like受体7/8激活剂结合起来.
- 给瘤小鼠进行皮下 (SNP- SC) 和静脉注射 (SNP- IV).
- 使用单细胞RNA测序来分析疫苗接种后瘤内髓细胞的变化.
主要成果:
- 这两种接种方式都诱导了瘤透的抗原特异性CD8+ T细胞.
- 静脉注射疫苗 (SNP- IV) 导致显著的瘤回归,依赖于全身I型干扰素.
- 通过SNP-IV疫苗接种减少了表达免疫调节基因特征的内单细胞 (Chil3,Anxa2,Wfdc17).
结论:
- 纳米粒子疫苗的静脉注射可以通过减少抑制性骨髓细胞有效地重塑TME.
- 结合T细胞诱导与TME调制是癌症免疫治疗的一个有前途的策略.
- 在小鼠中发现的免疫调节单细胞特征与人类癌症患者的不良结果相关.
相关概念视频
Tumor Immunotherapy
639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Cancer Vaccines
488
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
488
Cytotoxic T Cells-mediated Immune Response
1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K
Vaccinations
45.2K
Overview
45.2K
T Cell Activation and Clonal Selection
3.0K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
3.0K


